Cargando…

Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study

BACKGROUND: Previous studies have provided equivocal data on the use of miglustat as maintenance therapy in Gaucher disease type 1. We report findings from a clinical trial evaluating the effects of miglustat treatment in patients with stable type 1 Gaucher disease after enzyme therapy. METHODS: Adu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cox, Timothy M, Amato, Dominick, Hollak, Carla EM, Luzy, Cecile, Silkey, Mariabeth, Giorgino, Ruben, Steiner, Robert D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552937/ https://www.ncbi.nlm.nih.gov/pubmed/23270487 http://dx.doi.org/10.1186/1750-1172-7-102

Ejemplares similares

Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
por: Amato, Dominick, et al.
Publicado: (2018)

Review of miglustat for clinical management in Gaucher disease type 1
por: Ficicioglu, Can
Publicado: (2008)

Eye Movement Impairment Recovery in a Gaucher Patient Treated with Miglustat
por: Accardo, Agostino, et al.
Publicado: (2010)

Substrate reduction therapy with miglustat for type 1 Gaucher disease: A retrospective analysis from a single institution
por: Machaczka, Maciej, et al.
Publicado: (2012)

Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease
por: van Dussen, Laura, et al.
Publicado: (2014)

Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report
por: Giuffrida, Gaetano, et al.
Publicado: (2016)

An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
por: Hollak, Carla EM
Publicado: (2012)

Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series
por: Serratrice, Christine, et al.
Publicado: (2015)

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications
por: van Dussen, Laura, et al.
Publicado: (2014)

The cognitive profile of type 1 Gaucher disease patients
por: Biegstraaten, Marieke, et al.
Publicado: (2012)

Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome
por: Quraishi, Imran H., et al.
Publicado: (2021)

Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
por: Fiege, Lina, et al.
Publicado: (2023)

A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat
por: Remenova, Tatiana, et al.
Publicado: (2015)

Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C
por: Héron, Bénédicte, et al.
Publicado: (2012)

New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat
por: Wraith, James E, et al.
Publicado: (2009)

Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients
por: Smid, Bouwien E., et al.
Publicado: (2016)

Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study
por: Patterson, Marc C, et al.
Publicado: (2015)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Use of Ambroxol as Therapy for Gaucher Disease
por: Zhan, Xia, et al.
Publicado: (2023)

Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: a national French retrospective study
por: Freihuber, Cécile, et al.
Publicado: (2023)

Homozygous N396T mutation in Gaucher disease: Portuguese sisters with markedly different phenotypes
por: Kimball, Samantha, et al.
Publicado: (2011)

Miglustat in Niemann-Pick disease type C patients: a review
por: Pineda, Mercè, et al.
Publicado: (2018)

Corneal Alterations during Combined Therapy with Cyclodextrin/Allopregnanolone and Miglustat in a Knock-Out Mouse Model of NPC1 Disease
por: Hovakimyan, Marine, et al.
Publicado: (2011)

Design of trials for interrupting the transmission of endemic pathogens
por: Silkey, Mariabeth, et al.
Publicado: (2016)

Correction: The Autism Impact Measure (AIM): Meaningful Change Thresholds and Core Symptom Changes Over One Year from an Online Survey in the U.S.
por: Silkey, Mariabeth, et al.
Publicado: (2022)

Effect of Children’s Autism Spectrum Disorder Severity on Family Strain and Sleep Quality: A Cross-Sectional Online Survey in the U.S.
por: Durán-Pacheco, Gonzalo, et al.
Publicado: (2022)

The Autism Impact Measure (AIM): Meaningful Change Thresholds and Core Symptom Changes Over One Year from an Online Survey in the U.S.
por: Silkey, Mariabeth, et al.
Publicado: (2022)

Three cases of multi-generational Gaucher disease and colon cancer from an Ashkenazi Jewish family: A lesson for cascade screening
por: Hannah-Shmouni, Fady, et al.
Publicado: (2019)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study
por: Bone, Wilhelm, et al.
Publicado: (2007)

Effects of miglustat treatment in a patient affected by an atypical form of Tangier disease
por: Sechi, Annalisa, et al.
Publicado: (2014)

Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease
por: D'Arcangelo, G., et al.
Publicado: (2016)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience
por: Fischetto, Rita, et al.
Publicado: (2020)

Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry
por: Patterson, Marc C., et al.
Publicado: (2020)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1
por: Neßlauer, Anna-Maria, et al.
Publicado: (2019)

Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation
por: Terry, Paul D., et al.
Publicado: (2020)

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry
por: Denton, Christopher P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j6m4sfoebeapf767bhh46mgc2r